263 related articles for article (PubMed ID: 20685681)
41. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
Onuigbo MA
Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
[No Abstract] [Full Text] [Related]
42. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
43. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
[TBL] [Abstract][Full Text] [Related]
44. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
Xie W; Zheng F; Song X; Zhong B; Yan L
Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
46. [Debate concerning the optimal blockage of the renin-angiotensin system].
Choukroun G
Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
[No Abstract] [Full Text] [Related]
47. RAS inhibition in hypertension.
Ibrahim MM
J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
[TBL] [Abstract][Full Text] [Related]
48. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
[TBL] [Abstract][Full Text] [Related]
49. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Kubota T; Takeshita A
Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
[TBL] [Abstract][Full Text] [Related]
50. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
51. Renin-angiotensin-system blockade in the prevention of diabetes.
Ostergren J
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
[TBL] [Abstract][Full Text] [Related]
52. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
Robles NR; Ruiz Jiménez B; Hernández Gallego R; Ruiz-Calero R; Sánchez Casado E; Cubero JJ
Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
[TBL] [Abstract][Full Text] [Related]
53. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
54. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
Weir MR
Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
[TBL] [Abstract][Full Text] [Related]
55. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
56. Clinical and hemodynamic effects of renin-angiotensin system blockade in cardiac transplant recipients.
Karabsheh S; Verma DR; Jain M; Stoddard G; Brunisholz K; Stehlik J; Kfoury A; Gilbert E; Bader F
Am J Cardiol; 2011 Dec; 108(12):1836-9. PubMed ID: 22133132
[TBL] [Abstract][Full Text] [Related]
57. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
van der Zijl NJ; Moors CC; Goossens GH; Blaak EE; Diamant M
Diabetes Obes Metab; 2012 Jul; 14(7):586-95. PubMed ID: 22226145
[TBL] [Abstract][Full Text] [Related]
58. [ACE inhibitors continue to be first choice in the treatment of heart failure patients].
Gadsbøll N; Pedersen CT
Ugeskr Laeger; 2013 May; 175(22):1566-8. PubMed ID: 23721841
[TBL] [Abstract][Full Text] [Related]
59. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
Ueda S
J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
[TBL] [Abstract][Full Text] [Related]
60. [Role of RAAS inhibitors for the treatment of heart failure].
Murohara T
Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
